Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Oncology Reviews

Volumn 5, Issue 3, 2011, Pages 177-184

  Wenger, Justin B ^a   Santos, Napoleon ^a   Liu, Yanxia ^b   Dallas, Jennifer ^a   Subbiah, Sukanthini ^a   Hochwald, Steven ^c   Huang, Emina H ^c   Dang, Duyen T ^d   Allegra, Carmen J ^a   Luesch, Hendrik ^b   Dang, Long H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenic therapy; Hepatocellular carcinoma; HIF 1 ; HIF 2

Indexed keywords

ALPHA1 INTERFERON; AXITINIB; BEVACIZUMAB; DOXORUBICIN; ERLOTINIB; GEMCITABINE; OXALIPLATIN; PAZOPANIB; SORAFENIB; SUNITINIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG DEVELOPMENT; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 83255194116     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-011-0082-3     Document Type: Review

References (60)

1. Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27(9):1485-1491
2. Greten TF, Manns MP, Korangy F (2008) Immunotherapy of HCC. Rev Recent Clin Trials 3(1):31-39 (Pubitemid 351267024)
3. Perz JF et al (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529-538 (Pubitemid 44307383)
4. Thomas MB, Abbruzzese JL (2005) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23(31): 8093-81085.
5. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20-S37
6. Alberts SR et al (2007) Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc 82(5):628-637 (Pubitemid 46709432)
7. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257
8. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27-31
9. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21(3):505-515 (Pubitemid 30137936)
10. Gale NW et al (2002) Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 67:267-273 (Pubitemid 36775520)
11. Jain RK et al (2006) Lessons from phase III clinical trials on anti- VEGF therapy for cancer. Nat Clin Pract Oncol 3(1):24-40 (Pubitemid 43108832)
12. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884-896 (Pubitemid 350002890)
13. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342 (Pubitemid 38702844)
14. Bukowski RM (2004) New antiangiogenic agents for renal cell carcinoma: bevacizumab. Curr Oncol Rep 6(2):85-86
15. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
16. Sternberg CN et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. J Clin Oncol 28(6):1061-1068
17. Folkman J (2004) A novel anti-vascular therapy for cancer. Cancer Biol Ther 3(3):338-339 (Pubitemid 41350889)
18. Casanovas O et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299-309 (Pubitemid 41443415)
19. Mizukami Y et al (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11(9):992-997 (Pubitemid 41294446)
20. Yu JL et al (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295(5559):1526-1528 (Pubitemid 34174008)
21. Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220-231
22. Yao JC et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-1323
23. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591
24. Dai CX et al (2009) Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 9:418
25. Cheng AL et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
26. Richly H et al (2009) Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 45(4):579-587
27. Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69(2):223-240
28. Hoffmann K et al (2008) Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349
29. Cabibbo G et al (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 6(3):159-169
30. Wang B et al (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49(5):523-529
31. Virmani S et al (2008) Comparison of hypoxia-inducible factor- 1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 19(10): 1483-1489
32. Siegel AB et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26(18):2992-2998
33. Zhu AX et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12):1898-1903 (Pubitemid 46638989)
34. Thomas MB et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843-850
35. Faivre S et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10(8):794-800
36. Zhu AX et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27(18):3027-3035
37. Streubel B et al (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351(3):250-259 (Pubitemid 38916042)
38. Raza A, Franklin MJ, Dudek AZ (2010) Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85(8):593-598
39. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5(1):13-17 (Pubitemid 38121592)
40. Rubenstein JL et al (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2(4):306-314
41. Hendrix MJ et al (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3(6):411-421 (Pubitemid 37328845)
42. Burkitt K et al (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 8(5):1148-1156
43. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732 (Pubitemid 37328811)
44. Chun SY et al (2010) Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1a and HIF-2a target genes. Mol Cancer 9(1):293
45. Unruh A et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22(21):3213-3220 (Pubitemid 36712933)
46. Bos R et al (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93(4):309-314 (Pubitemid 32219818)
47. Schindl M et al (2002) Overexpression of hypoxia-inducible factor 1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8(6): 1831-1837 (Pubitemid 34633742)
48. Koukourakis MI et al (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53(5):1192-1202 (Pubitemid 34787855)
49. Aebersold DM et al (2001) Expression of hypoxia-inducible factor- 1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61(7):2911-2916 (Pubitemid 32691934)
50. Kurokawa T et al (2003) Overexpression of hypoxia-induciblefactor 1alpha (HIF-1alpha) in oesophageal squamous cellcarcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89(6):1042-1047 (Pubitemid 37239209)
51. Birner P et al (2000) Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60(17):4693-4696
52. Birner P et al (2001) Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7(6):1661-1668 (Pubitemid 32708633)
53. Birner P et al (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92(1):165-171 (Pubitemid 32623053)
54. Bachtiary B et al (2003) Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9(6):2234-2240 (Pubitemid 36687648)
55. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29(5):625-634
56. Semenza GL (2009) HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 15(33): 3839-3843
57. Melillo G (2007) Hypoxia-inducible factor 1 inhibitors. Methods Enzymol 435:385-402
58. Escuin D, Simons JW, Giannakakou P (2004) Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 3(7):608-611 (Pubitemid 41351095)
59. Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2(10):803-811 (Pubitemid 37361812)
60. Scheuermann TH et al (2009) Artificial ligand binding within the HIF2 alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci U S A 106(2):450-455